

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 6, 2020**

**EXACT SCIENCES CORPORATION**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or Other Jurisdiction  
of Incorporation)

**001-35092**

(Commission  
File Number)

**02-0478229**

(I.R.S. Employer  
Identification No.)

**441 Charmany Drive**

**Madison, WI 53719**

(Address of Principal Executive Offices)(Zip Code)

Registrant's telephone number, including area code: **(608) 284-5700**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Stock, \$0.01 par value per share</b>	<b>EXAS</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

## **2.02. Results of Operations and Financial Conditions.**

On May 6, 2020, Exact Sciences Corporation announced its financial results for the quarter ended March 31, 2020. A copy of the press release is being furnished as Exhibit 99 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and Exhibit 99 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

## **9.01. Financial Statements and Exhibits.**

### **Exhibits**

The exhibits required to be filed as a part of this Current Report on Form 8-K are listed below and incorporated herein by reference.

<b>Exhibit No.</b>	<b>Exhibit Description</b>
<a href="#">99</a>	Press release, dated May 6, 2020, issued by Exact Sciences Corporation, furnished herewith.
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EXACT SCIENCES CORPORATION**

Date: May 6, 2020

By: /s/ Jeffrey T. Elliott

Jeffrey T. Elliott

Chief Financial Officer

**Investor Contact:**

Megan Jones  
 Exact Sciences Corp.  
 meganjones@exactsciences.com  
 608-535-8815

**Media Contact:**

Cara Connelly  
 Exact Sciences Corp.  
 cconnelly@exactsciences.com  
 608-284-5735

For Immediate Release

### Exact Sciences Announces First Quarter 2020 Results

**MADISON, Wis.**, May 6, 2020 — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of \$347.8 million for the first quarter ended Mar. 31, 2020, compared to \$162.0 million for the same period of 2019.

"Even in unprecedented times, cancer doesn't stop. The coronavirus pandemic highlights and increases the need for novel ways to screen for cancer, detect it early, and guide treatment. Our Cologuard, Oncotype DX, and Paradigm tests meet that need," said Kevin Conroy, chairman and CEO. "In a world that is trying to avoid unnecessary physician office visits, invasive procedures, and treatments, our tests and deep pipeline are more valuable now than ever. We plan to play an even greater role in cancer screening and guiding therapy decisions after the coronavirus pandemic abates."

**First Quarter 2020 Financial Results**

*For the three-month period ended March 31, 2020, as compared to the same period of 2019 (where applicable):*

- Total revenue was \$347.8 million, compared to \$162.0 million
- Screening revenue was \$219.5 million, an increase of 35 percent
- Precision Oncology revenue was \$128.4 million
- Gross margin including amortization of acquired intangible assets was 71 percent, and non-GAAP gross margin excluding amortization of acquired intangible assets was 77 percent
- Net loss was \$105.7 million, or \$0.71 per share, compared to a net loss of \$82.9 million, or \$0.66 per share
- EBITDA was \$(51.0) million and adjusted EBITDA was \$(8.2) million
- Non-cash interest expense related to convertible debt was \$22.5 million, which included a non-cash loss on extinguishment of debt of \$8.0 million, compared to \$19.6 million, which included a non-cash loss on extinguishment of debt of \$10.6 million
- Cash, cash equivalents, and marketable securities were \$1.2 billion at the end of the quarter, including \$975.5 million, net, raised in relation to the issuance of new convertible notes and the repayment of a portion of previously issued convertible notes

Screening includes laboratory service revenue from Cologuard and revenue from Biomatrix products. Precision Oncology includes laboratory service revenue from global Oncotype DX products and the recent Paradigm acquisition.

**Non-GAAP Disclosure**

In addition to the company's financial results determined in accordance with U.S. GAAP, the company provides non-GAAP measures that it determines to be useful in evaluating its operating performance. The company presents EBITDA, adjusted EBITDA, as well as non-GAAP gross margin and non-GAAP gross profit. EBITDA and adjusted EBITDA consist of net loss after adjustment for those items shown in the table below. The company defines non-GAAP gross profit and non-GAAP gross margin as GAAP gross profit and GAAP gross margin, respectively, excluding amortization of acquired intangible assets. The amortization of acquisition-related intangible assets used in the calculation of non-GAAP gross profit and non-GAAP gross margin pertain only to the amortization associated with developed technology acquired and recorded through purchase accounting transactions. The amortization of these intangible assets will recur in future periods until such intangible assets have

---

been fully amortized. The company believes that these non-GAAP measures are useful in evaluating the company's operating performance. The company uses this non-GAAP financial information to evaluate ongoing operations and for internal planning and forecasting purposes. Non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. For example, non-GAAP gross margin and non-GAAP gross profit exclude the amortization of acquired intangible assets although such measures include the revenue associated with the acquisitions. For a reconciliation of these non-GAAP measures to GAAP, see below "EBITDA and Adjusted EBITDA Reconciliations."

#### **First Quarter Conference Call & Webcast**

Company management will host a conference call and webcast on Wednesday, May 6, 2020, at 5 p.m. ET to discuss first quarter 2020 results. The webcast will be available at [www.exactsciences.com](http://www.exactsciences.com). Domestic callers should dial 833-235-7650 and international callers should dial +1-647-689-4171.

An archive of the webcast will be available at [www.exactsciences.com](http://www.exactsciences.com). A replay of the conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally. The access code for the replay of the call is 7874149. The webcast, conference call and replay are open to all interested parties.

#### **About Cologuard**

Cologuard was approved by the FDA in August 2014, and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the American Cancer Society's (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use Cologuard if you have had precancer, have inflammatory bowel disease and certain hereditary syndromes, or have a personal or family history of colorectal cancer. Cologuard is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. Cologuard performance in repeat testing has not been evaluated.

The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for diagnostic colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again.

Medicare and most major insurers cover Cologuard. For more information about Cologuard, visit [www.cologuardtest.com](http://www.cologuardtest.com). Rx only.

#### **About Oncotype DX**

The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score® test predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention, and the Oncotype DX AR-V7 Nucleus Detect™ test helps determine which patients with metastatic castration-resistant prostate cancer (mCRPC) are resistant to androgen receptor (AR)-targeted therapies. The Oncotype DX AR-V7 Nucleus Detect test is performed by Epic Sciences at its centralized, CLIA-certified laboratory in San Diego and offered exclusively by Exact Sciences. With more than 1 million patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit [www.OncotypeIQ.com](http://www.OncotypeIQ.com), [www.MyBreastCancerTreatment.org](http://www.MyBreastCancerTreatment.org) or [www.MyProstateCancerTreatment.org](http://www.MyProstateCancerTreatment.org).

#### **About Exact Sciences Corp.**

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at [www.exactsciences.com](http://www.exactsciences.com), follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

---

## **Forward-Looking Statements**

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, expectations, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the success of our efforts to facilitate patient access to Cologuard via telehealth; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition for our products and services; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Society of Clinical Oncology, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services and assess potential market opportunities; our ability to effectively enter into and utilize strategic partnerships, such as through our Promotion Agreement with Pfizer, Inc., and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; our ability to manage an international business and our expectations regarding our international expansion and opportunities; the potential effects of foreign currency exchange rate fluctuations and our efforts to hedge such effects; the possibility that the anticipated benefits from our combination with Genomic Health cannot be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Genomic Health's operations will be greater than expected and the possibility of disruptions to our business during integration efforts and strain on management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

---

**EXACT SCIENCES CORPORATION**  
**Selected Unaudited Financial Information**  
**Condensed Consolidated Statements of Operations**  
(Amounts in thousands, except per share data)

	Three Months Ended March 31,	
	2020	2019
Revenue	\$ 347,821	\$ 162,043
Operating expenses		
Cost of sales (exclusive of amortization of acquired intangible assets)	81,606	42,827
Research and development	43,509	31,785
Sales and marketing	167,749	90,939
General and administrative	113,991	63,806
Amortization of acquired intangible assets	23,339	760
Total operating expenses	430,194	230,117
Loss from operations	(82,373)	(68,074)
Other income (expense)		
Investment income, net	97	6,655
Interest expense	(25,153)	(21,990)
Total other income (expense)	(25,056)	(15,335)
Net loss before tax	(107,429)	(83,409)
Income tax benefit	1,732	470
Net loss	\$ (105,697)	\$ (82,939)
Net loss per share—basic and diluted	\$ (0.71)	\$ (0.66)
Weighted average common shares outstanding—basic and diluted	148,151	126,248

**EXACT SCIENCES CORPORATION**  
**Selected Unaudited Financial Information**  
**Condensed Consolidated Balance Sheets**  
(Amounts in thousands)

	March 31, 2020	December 31, 2019
<b>Assets</b>		
Cash and cash equivalents	\$ 701,054	\$ 177,254
Marketable securities	530,062	146,401
Accounts receivable, net	140,046	130,667
Inventory, net	69,424	61,724
Prepaid expenses and other current assets	43,732	40,913
Property, plant and equipment, net	465,476	455,325
Operating lease right-of-use assets	124,369	126,444
Goodwill	1,237,161	1,203,197
Intangible assets, net	1,128,261	1,143,550
Other long-term assets, net	21,540	20,293
Total assets	\$ 4,461,125	\$ 3,505,768
<b>Liabilities and stockholders' equity</b>		
Total current liabilities	\$ 243,581	\$ 236,494
Convertible notes, net	1,514,306	803,605
Long-term debt, less current portion	—	24,032
Other long-term liabilities	47,252	34,911
Operating lease liabilities, less current portion	118,333	118,665
Total stockholders' equity	2,537,653	2,288,061
Total liabilities and stockholders' equity	\$ 4,461,125	\$ 3,505,768

**EXACT SCIENCES CORPORATION**  
**Selected Unaudited Financial Information**  
**EBITDA and Adjusted EBITDA Reconciliations**  
(Amounts in thousands)

	Three Months Ended March 31,	
	2020	2019
Net loss	\$ (105,697)	\$ (82,939)
Interest expense	17,199	11,432
Investment income	(97)	(6,655)
Depreciation and amortization	39,345	7,135
Income tax benefit	(1,732)	(470)
EBITDA	\$ (50,982)	\$ (71,497)
Stock-based compensation	26,742	16,166
Loss on settlement of convertible notes	7,954	10,558
Acquisition and integration costs (1)	8,048	—
Adjusted EBITDA	\$ (8,238)	\$ (44,773)

(1) Represents acquisition and related integration costs incurred as a result of the company's combination with Genomic Health. Acquisition and integration costs were \$8.0 million for the three months ended March 31, 2020. The costs primarily consist of legal and other professional service fees and incremental stock-based compensation including the fair value of stock awards assumed by the company in connection with the Genomic Health combination. Legal, severance, and other professional service fees were \$5.2 million for the three months ended March 31, 2020. Incremental stock-based compensation including the fair value of assumed stock awards was \$2.8 million for the three months ended March 31, 2020.

**EXACT SCIENCES CORPORATION**  
**Selected Unaudited Financial Information**  
**Non-GAAP Gross Profit and Non-GAAP Gross Margin**  
**(Amounts in thousands)**

	<b>Three Months Ended March 31,</b>	
	<b>2020</b>	<b>2019</b>
Revenue	\$ 347,821	\$ 162,043
Cost of sales (exclusive of amortization of acquired intangible assets)	81,606	42,827
Amortization of acquired intangible assets (1)	20,464	425
Gross profit	\$ 245,751	\$ 118,791
Gross margin	71%	73%
Amortization of acquired intangible assets (1)	20,464	425
Non-GAAP gross profit	\$ 266,215	\$ 119,216
Non-GAAP gross margin	77%	74%

(1) Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of sales.